Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...
A recent study finds that despite biosimilar use rising to 60% to 86% for three cancer drugs, predicted savings don’t match ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback